留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

非肥胖型非酒精性脂肪性肝病的病因及治疗进展

李洋洋 谢正元

李洋洋, 谢正元. 非肥胖型非酒精性脂肪性肝病的病因及治疗进展[J]. 临床肝胆病杂志, 2021, 37(2): 452-457. DOI: 10.3969/j.issn.1001-5256.2021.02.043
引用本文: 李洋洋, 谢正元. 非肥胖型非酒精性脂肪性肝病的病因及治疗进展[J]. 临床肝胆病杂志, 2021, 37(2): 452-457. DOI: 10.3969/j.issn.1001-5256.2021.02.043
LI YY, XIE ZY. Advances in the etiology and treatment of non-obese nonalcoholic fatty liver disease [J]. J Clin Hepatol, 2021, 37(2): 452-457. DOI: 10.3969/j.issn.1001-5256.2021.02.043
Citation: LI YY, XIE ZY. Advances in the etiology and treatment of non-obese nonalcoholic fatty liver disease [J]. J Clin Hepatol, 2021, 37(2): 452-457. DOI: 10.3969/j.issn.1001-5256.2021.02.043

非肥胖型非酒精性脂肪性肝病的病因及治疗进展

DOI: 10.3969/j.issn.1001-5256.2021.02.043
基金项目: 

国自然科学基金 81860119

江西省自然科学基金资助项目 20181BAB205011

详细信息
    作者简介:

    李洋洋(1996—),男,主要从事非酒精性脂肪肝相关研究

    通讯作者:

    谢正元,xzyxzy1230@163.com

  • 作者贡献声明:李洋洋负责参与收集数据,资料分析,撰写论文,修改论文;谢正元负责拟定写作思路,指导撰写文章并最后定稿。
  • 中图分类号: R575.5

Advances in the etiology and treatment of non-obese nonalcoholic fatty liver disease

  • 摘要: 随着非酒精性脂肪性肝病(NAFLD)在非肥胖人群中的流行,越来越多的研究探讨了NAFLD在非肥胖人群中的意义。与肥胖型NAFLD患者相比,非肥胖型NAFLD患者虽缺乏肥胖表型,但仍存在代谢紊乱,其发生代谢性疾病和心血管疾病的风险更大。目前针对非肥胖型NAFLD尚无治疗相关的有效药物,且现有的治疗方式各有优势,但都存在一定的局限性。从非肥胖型NAFLD的病因及治疗进展方面进行综述,为指导非肥胖型NAFLD临床治疗提供参考。
  • 图  1  非肥胖型NAFLD的危险因素

    图  2  非肥胖型NAFLD治疗方案

    注:LAL,溶酶体酸性脂肪酶。

  • [1] LONARDO A, NASCIMBENI F, MAURANTONIO M, et al. Nonalcoholic fatty liver disease: Evolving paradigms[J]. World J Gastroenterol, 2017, 23(36): 6571-6592. DOI: 10.3748/wjg.v23.i36.6571
    [2] NADERIAN M, KOLAHDOOZAN S, SHARIFI AS, et al. Assessment of lean patients with non-alcoholic fatty liver disease in a middle income country; Prevalence and its association with metabolic disorders: A cross-sectional study[J]. Arch Iran Med, 2017, 20(4): 211-217.
    [3] ZENG J, YANG RX, SUN C, et al. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2020, 26(15): 1792-1804. DOI: 10.3748/wjg.v26.i15.1792
    [4] YE Q, ZOU B, YEO YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5(8): 739-752. DOI: 10.1016/S2468-1253(20)30077-7
    [5] WANG AY, DHALIWAL J, MOUZAKI M. Lean non-alcoholic fatty liver disease[J]. Clin Nutr, 2019, 38(3): 975-981. DOI: 10.1016/j.clnu.2018.08.008
    [6] KIM SH, PARK HY, LEE HS, et al. Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity[J]. Sci Rep, 2020, 10(1): 1025. DOI: 10.1038/s41598-020-57894-y
    [7] AHMED M. Non-alcoholic fatty liver disease in 2015[J]. World J Hepatol, 2015, 7(11): 1450-1459. DOI: 10.4254/wjh.v7.i11.1450
    [8] TOBARI M, HASHIMOTO E, TANIAI M, et al. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign[J]. J Gastroenterol Hepatol, 2019, 34(8): 1404-1410. DOI: 10.1111/jgh.14585
    [9] GONZALEZ-CANTERO J, MARTIN-RODRIGUEZ JL, GONZALEZ-CANTERO A, et al. Insulin resistance in lean and overweight non-diabetic Caucasian adults: Study of its relationship with liver triglyceride content, waist circumference and BMI[J]. PLoS One, 2018, 13(2): e0192663. DOI: 10.1371/journal.pone.0192663
    [10] HONDA Y, YONEDA M, KESSOKU T, et al. Characteristics of non-obese non-alcoholic fatty liver disease: Effect of genetic and environmental factors[J]. Hepatol Res, 2016, 46(10): 1011-1018. DOI: 10.1111/hepr.12648
    [11] NISHIOJI K, MOCHIZUKI N, KOBAYASHI M, et al. The impact of PNPLA3 rs738409 genetic polymorphism and weight gain ≥10 kg after age 20 on non-alcoholic fatty liver disease in non-obese Japanese individuals[J]. PLoS One, 2015, 10(10): e0140427. DOI: 10.1371/journal.pone.0140427
    [12] LU FB, HU ED, XU LM, et al. The relationship between obesity and the severity of non-alcoholic fatty liver disease: Systematic review and meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(5): 491-502. DOI: 10.1080/17474124.2018.1460202
    [13] TU LN, SHOWALTER MR, CAJKA T, et al. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice[J]. Sci Rep, 2017, 7(1): 6120. DOI: 10.1038/s41598-017-05040-6
    [14] BASARANOGLU M, BASARANOGLU G, BUGIANESI E. Carbohydrate intake and nonalcoholic fatty liver disease: Fructose as a weapon of mass destruction[J]. Hepatobiliary Surg Nutr, 2015, 4(2): 109-116.
    [15] LI C, GUO P, OKEKUNLE AP, et al. Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients[J]. J Gastroenterol Hepatol, 2019, 34(1): 256-262. DOI: 10.1111/jgh.14360
    [16] KIM D, KIM WR. Nonobese fatty liver disease[J]. Clin Gastroenterol Hepatol, 2017, 15(4): 474-485. DOI: 10.1016/j.cgh.2016.08.028
    [17] SUN YY, LIANG L, WANG XY, et al. Improvement effect of dapagliflozin on liver function in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease and its mechanism[J]. J Jilin Univ (Med Edit), 2020, 46(1): 116-120. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-BQEB202001022.htm

    孙媛媛, 梁丽, 王笑烨, 等. 达格列净对2型糖尿病并发非酒精性脂肪性肝病患者肝功能的改善作用及其机制[J]. 吉林大学学报(医学版), 2020, 46(1): 116-120. https://www.cnki.com.cn/Article/CJFDTOTAL-BQEB202001022.htm
    [18] YANG CW, LIU X, LIU XR, et al. The relationship between waist circumference and new-onset non-alcoholic fatty liver disease in non-obese patients with diabetes mellitus[J]. Tianjin Med J, 2015, 43(1): 74-77. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ201501021.htm

    杨春伟, 刘星, 刘秀荣, 等. 糖尿病非肥胖人群腰围与新发非酒精性脂肪肝的关系[J]. 天津医药, 2015, 43(1): 74-77. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ201501021.htm
    [19] ZHENG X, GONG L, LUO R, et al. Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults[J]. Lipids Health Dis, 2017, 16(1): 202. DOI: 10.1186/s12944-017-0531-5
    [20] KIM JJ, KIM D, YIM JY, et al. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2017, 45(11): 1403-1412. DOI: 10.1111/apt.14058
    [21] WONG VW, WONG GL, CHAN RS, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2018, 69(6): 1349-1356. DOI: 10.1016/j.jhep.2018.08.011
    [22] JIN YJ, KIM KM, HWANG S, et al. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: Analysis of biopsies of living liver donors[J]. J Gastroenterol Hepatol, 2012, 27(8): 1341-1347. DOI: 10.1111/j.1440-1746.2012.07165.x
    [23] TAKAHASHI H, ONO M, HYOGO H, et al. Biphasic effect of alcohol intake on the development of fatty liver disease[J]. J Gastroenterol, 2015, 50(11): 1114-1123. DOI: 10.1007/s00535-015-1058-z
    [24] ZHOU Q, SU J, JI MY. Progress in the treatment of nonalcoholic fatty liver disease[J]. China Med Herald, 2020, 17(6): 26-29. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202006008.htm

    周谦, 苏娟, 季梦遥. 非酒精性脂肪性肝病的治疗研究进展[J]. 中国医药导报, 2020, 17(6): 26-29. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202006008.htm
    [25] ATTIA SL, SOFTIC S, MOUZAKI M. Evolving role for pharmacotherapy in NAFLD/NASH[J]. Clin Transl Sci, 2020.[Epub ahead of print]
    [26] FIORUCCI S, BIAGIOLI M, SEPE V, et al. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)[J]. Expert Opin Investig Drugs, 2020, 29(6): 623-632. DOI: 10.1080/13543784.2020.1763302
    [27] TANG Y, HUANG J, ZHANG WY, et al. Effects of probiotics on nonalcoholic fatty liver disease: A systematic review and meta-analysis[J]. Therap Adv Gastroenterol, 2019, 12: 1756284819878046.
    [28] ZHOU Y, ZHENG T, CHEN H, et al. Microbial intervention as a novel target in treatment of non-alcoholic fatty liver disease progression[J]. Cell Physiol Biochem, 2018, 51(5): 2123-2135. DOI: 10.1159/000495830
    [29] XU RH, XIN QF. Efficacy of Ezetimibe in the treatment of non-obese patients with non-alcoholic fatty liver disease[J]. Chin J Convalescent Med, 2017, 26(7): 760-762. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGLX201707041.htm

    许瑞华, 辛庆锋. 依折麦布治疗非肥胖的非酒精性脂肪肝患者疗效观察[J]. 中国疗养医学, 2017, 26(7): 760-762. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGLX201707041.htm
    [30] ENJOJI M, MACHIDA K, KOHJIMA M, et al. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease[J]. Lipids Health Dis, 2010, 9: 29. DOI: 10.1186/1476-511X-9-29
    [31] SUN GP, CHEN YM, MENG J. Clinical observation on rosiglitazone in the treatment of non-obese type 2 diabetic mellitus with fatty liverr[J]. Clin J Chin Med, 2014, 6(15): 63-64, 67. (in Chinese) DOI: 10.3969/j.issn.1674-7860.2014.15.029

    孙广平, 陈奕名, 孟君. 罗格列酮对非肥胖2型糖尿病合并脂肪肝的疗效观察[J]. 中医临床研究, 2014, 6(15): 63-64, 67. DOI: 10.3969/j.issn.1674-7860.2014.15.029
    [32] FERNÁNDEZ-MARTÍNEZ E, LIRA-ISLAS IG, CARIÑO-CORTÉS R, et al. Dietary chia seeds (Salvia hispanica) improve acute dyslipidemia and steatohepatitis in rats[J]. J Food Biochem, 2019, 43(9): e12986.
    [33] BURTON BK, BALWANI M, FEILLET F, et al. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency[J]. N Engl J Med, 2015, 373(11): 1010-1020. DOI: 10.1056/NEJMoa1501365
    [34] QU YL, WANG YC, WAN JX. Association of nonalcoholic fatty liver disease with vitamin D and bone mineral density[J]. J Clin Hepatol, 2019, 35(9): 2021-2025. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.09.027

    曲玉蕾, 王迎春, 万金鑫. 非酒精性脂肪性肝病与血清维生素D及骨密度的关系[J]. 临床肝胆病杂志, 2019, 35(9): 2021-2025. DOI: 10.3969/j.issn.1001-5256.2019.09.027
    [35] ZHAI HL, WANG NJ, HAN B, et al. Low vitamin D levels and non-alcoholic fatty liver disease, evidence for their independent association in men in East China: A cross-sectional study (Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (SPECT-China))[J]. Br J Nutr, 2016, 115(8): 1352-1359. DOI: 10.1017/S0007114516000386
    [36] DABBAGHMANESH MH, DANAFAR F, ESHRAGHIAN A, et al. Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: A randomized double blind placebo controlled trial[J]. Diabetes Metab Syndr, 2018, 12(4): 513-517. DOI: 10.1016/j.dsx.2018.03.006
    [37] DASARATHY J, VARGHESE R, FELDMAN A, et al. Patients with nonalcoholic fatty liver disease have a low response rate to vitamin D supplementation[J]. J Nutr, 2017, 147(10): 1938-1946. DOI: 10.3945/jn.117.254292
    [38] SHIMOKOBE H, SUMIDA Y, TANAKA S, et al. Human placental extract treatment for non-alcoholic steatohepatitis non-responsive to lifestyle intervention: A pilot study[J]. Hepatol Res, 2015, 45(9): 1034-1040. DOI: 10.1111/hepr.12432
    [39] POLCE SA, BURKE C, FRANÇA LM, et al. Ellagic acid alleviates hepatic oxidative stress and insulin resistance in diabetic female rats[J]. Nutrients, 2018, 10(5): 531. DOI: 10.3390/nu10050531
    [40] LI JJ, GAO H, LV Y, et al. Zeaxanthin dipalmitate alleviates hepatic injury induced by superimposed chronic hepatitis B and non-alcoholic steatohepatitis in non-obese mice[J]. J Asian Nat Prod Res, 2017, 19(9): 910-923. DOI: 10.1080/10286020.2017.1349759
    [41] CRUZ ACD, BUGIANESI E, GEORGE J, et al. Characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2014, 146(Suppl 1): s909.
    [42] NIRIELLA MA, KASTURIRATNE A, PATHMESWARAN A, et al. Lean non-alcoholic fatty liver disease (lean NAFLD): Characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka[J]. Hepatol Int, 2019, 13(3): 314-322. DOI: 10.1007/s12072-018-9916-4
    [43] KUMAR R, RASTOGI A, SHARMA MK, et al. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease?[J]. Indian J Endocrinol Metab, 2013, 17(4): 665-671. DOI: 10.4103/2230-8210.113758
  • 加载中
图(2)
计量
  • 文章访问数:  39
  • HTML全文浏览量:  7
  • PDF下载量:  19
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-06-13
  • 修回日期:  2020-09-19
  • 刊出日期:  2021-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回